Current Clinical Trials

Duke Gastrointestinal Cancers Program is currently seeking people to participate in the following clinical trials:

• Phase I Study of Capecitabine, Oxaliplatin, Bevacizumab, and Dasatinib for Patients With Advanced Solid Tumors or Metastatic Colorectal Cancer
  The primary purpose of this study is to find the highest tolerated dose of the study drugs: capecitabine, oxaliplatin, bevacizumab, and dasatinib given in combination to subjects with advanced solid tumors.
• Phase IB Study of Sorafenib for Patient With Locally Advanced or Metastatic Carcinoma and Child's B Cirrhosis
  This Phase I trial is studying the side effects and best dose of sorafenib in treating patients with locally advanced or metastatic liver cancer and cirrhosis.
• Phase II Study of GSK1363089 (Formerly XL880) Administered Orally to Subjects With Metastatic Gastric Cancer
  This clinical study is being conducted at multiple sites to determine the best confirmed response rate, safety, and tolerability of GSK1363089 treatment in metastatic gastric carcinoma.
• Multicenter, Blinded Efficacy and Safety Study of Pasireotide LAR vs Octreotide LAR in Patients With Metastatic Carcinoid Tumors Whose Disease-Related Symptoms Are Inadequately Controlled by Somatostatin Analogues
  Participate in a study for patients with metastatic carcinoid tumors whose disease-related symptoms are inadequately controlled by somatostatin analogues.
• Phase II Study of Oxaliplatin, Capecitabine, and Bevacizumab in the Treatment of Metastatic Esophagogastric Adenocarcinomas
  Participate in a clinical trial for metastic esophagogastric adenocarcinomas.
• Phase I Open Label/ Phase II Multi-center Study Investigating the Combination of RAD001 and Sorafenib (Nexavar®) in Patients With Advanced Hepatocellular Carcinoma
  Participate in a study for patients with advanced hepatocellular carcinoma.
• Phase I, Open-Label, Dose-Escalation, Multidose Study of CDX-1307, a Mannose Receptor-Targeted hCG-β Vaccine, in Patients With Incurable Breast, Colorectal, Pancreatic, Ovarian, or Bladder Cancer (CDX-1307-01)
  Participate in a clinical study for patients with incurable breast, colorectal, pancreatic, ovarian, or bladder cancer.
• Phase I Study of the Combination of Gemcitabine Plus Dasatinib in Patients With Refractory Solid Tumors With an Expanded Cohort in Advanced Pancreatic Cancer
  Participate in a clinical trial for patients with refractory solid tumors.